2,5,8,11,14,17,20,23-Octaoxapentacosan-25-amine → (4S,7S,10S,13S)-10-benzyl-15-hydroxy-7,13-diisobutyl-15-methyl-1-morpholino-2,5,8,11,14-pentaoxo-4-phenethyl-3,6,9,12-tetraazahexadecan-16-yl 27-oxo-2,5,8,11,14,17,20,23-octaoxa-26-azadotriacontane-32-sulfonate

HRID 630627Notes

Reaction equation

[OH:1][C@@:2]([CH3:64])([C:16](=[O:63])[C@@H:17]([NH:22][C:23](=[O:62])[C@@H:24]([NH:32][C:33](=[O:61])[C@@H:34]([NH:39][C:40](=[O:60])[C@@H:41]([NH:50][C:51](=[O:59])[CH2:52][N:53]1[CH2:58][CH2:57][O:56][CH2:55][CH2:54]1)[CH2:42][CH2:43][C:44]1[CH:49]=[CH:48][CH:47]=[CH:46][CH:45]=1)[CH2:35][CH:36]([CH3:38])[CH3:37])[CH2:25][C:26]1[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=1)[CH2:18][CH:19]([CH3:21])[CH3:20])[CH2:3][O:4][S:5]([CH2:8][CH2:9][CH2:10][CH2:11][CH2:12][C:13](O)=[O:14])(=[O:7])=[O:6].[CH3:65][O:66][CH2:67][CH2:68][O:69][CH2:70][CH2:71][O:72][CH2:73][CH2:74][O:75][CH2:76][CH2:77][O:78][CH2:79][CH2:80][O:81][CH2:82][CH2:83][O:84][CH2:85][CH2:86][O:87][CH2:88][CH2:89][NH2:90]>>[O:14]=[C:13]([CH2:12][CH2:11][CH2:10][CH2:9][CH2:8][S:5]([O:4][CH2:3][C:2]([OH:1])([CH3:64])[C:16](=[O:63])[C@H:17]([CH2:18][CH:19]([CH3:20])[CH3:21])[NH:22][C:23](=[O:62])[C@H:24]([CH2:25][C:26]1[CH:27]=[CH:28][CH:29]=[CH:30][CH:31]=1)[NH:32][C:33](=[O:61])[C@H:34]([CH2:35][CH:36]([CH3:37])[CH3:38])[NH:39][C:40](=[O:60])[C@H:41]([CH2:42][CH2:43][C:44]1[CH:49]=[CH:48][CH:47]=[CH:46][CH:45]=1)[NH:50][C:51](=[O:59])[CH2:52][N:53]1[CH2:54][CH2:55][O:56][CH2:57][CH2:58]1)(=[O:7])=[O:6])[NH:90][CH2:89][CH2:88][O:87][CH2:86][CH2:85][O:84][CH2:83][CH2:82][O:81][CH2:80][CH2:79][O:78][CH2:77][CH2:76][O:75][CH2:74][CH2:73][O:72][CH2:71][CH2:70][O:69][CH2:68][CH2:67][O:66][CH3:65]

Participants

Reactant 2

HCID 513409632,5,8,11,14,17,20,23-Octaoxapentacosan-25-amine

HCID 867153746-({[(2R,4S)-2-Hydroxy-2,6-dimethyl-4-[(2S)-2-[(2S)-4-methyl-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]-4-phenylbutanamido]pentanamido]-3-phenylpropanamido]-3-oxoheptyl]oxy}sulfonyl)hexanoic acid

Product 1

HCID 86715373(4S,7S,10S,13S)-10-benzyl-15-hydroxy-7,13-diisobutyl-15-methyl-1-morpholino-2,5,8,11,14-pentaoxo-4-phenethyl-3,6,9,12-tetraazahexadecan-16-yl 27-oxo-2,5,8,11,14,17,20,23-octaoxa-26-azadotriacontane-32-sulfonate

Procedure

6-({[(2R,4S)-2-Hydroxy-2,6-dimethyl-4-[(2S)-2-[(2S)-4-methyl-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]-4-phenylbutanamido]pentanamido]-3-phenylpropanamido]-3-oxoheptyl]oxy}sulfonyl)hexanoic acid and 2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine (Quanta Biodesign) were reacted following General PEGylation Conditions, Method D.

Sources & evidence

ORD record: ord-e32ea66ac10b475baecb0cb146f3663c
Source dataset: uspto-grants-2016_04
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US09315542B2

Reaction notes

Loading…